Details for New Drug Application (NDA): 214501
✉ Email this page to a colleague
NDA 214501 describes BRIVARACETAM, which is a drug marketed by Aurobindo Pharma Ltd, Lupin Ltd, Sunshine, and Zydus Pharms, and is included in four NDAs. Additional details are available on the BRIVARACETAM profile page.
The generic ingredient in BRIVARACETAM is brivaracetam. One supplier is listed for this compound. Additional details are available on the brivaracetam profile page.
The generic ingredient in BRIVARACETAM is brivaracetam. One supplier is listed for this compound. Additional details are available on the brivaracetam profile page.
Summary for 214501
| Tradename: | BRIVARACETAM |
| Applicant: | Zydus Pharms |
| Ingredient: | brivaracetam |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Oct 3, 2022 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Oct 3, 2022 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Oct 3, 2022 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
